Sphingolipid signaling in renal fibrosis.

Huwiler A; Pfeilschifter J

doi:10.1016/j.matbio.2018.01.006

Back

Journal article

Sphingolipid signaling in renal fibrosis.

Huwiler A Institute of Pharmacology, University of Bern, Inselspital INO-F, CH-3010 Bern, Switzerland. Electronic address: huwiler@pki.unibe.ch.
Pfeilschifter J Institute of General Pharmacology and Toxicology, University Hospital Frankfurt, Goethe- University, Frankfurt am Main, Germany.

2018-01-19

Published in:

Matrix biology : journal of the International Society for Matrix Biology. - 2018

Phosphotransferases (Alcohol Group Acceptor)

Sphingomyelin Phosphodiesterase

English Over the last decade, various sphingolipid subspecies have gained increasing attention as important signaling molecules that regulate a multitude of physiological and pathophysiological processes including inflammation and tissue remodeling. These mediators include ceramide, sphingosine 1-phosphate (S1P), the cerebroside glucosylceramide, lactosylceramide, and the gangliosides GM3 and Gb3. These lipids have been shown to accumulate in various chronic kidney diseases that typically end in renal fibrosis and ultimately renal failure. This review will summarize the effects and contributions of those enzymes that regulate the generation and interconversion of these lipids, notably the acid sphingomyelinase, the acid sphingomyelinase-like protein SMPDL3B, the sphingosine kinases, the S1P lyase, the glucosylceramide synthase, the GM3 synthase, and the α-galactosidase A, to renal fibrotic diseases. Strategies of manipulating these enzymes for therapeutic purposes and the impact of existing drugs on renal pathologies will be discussed.

Language